Inhibition of EZH2 protein could treat multiple myeloma
A study led by Helena Jernberg Wiklund, Uppsala University/SciLifeLab, shows how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease. The cancer form multiple myeloma is today incurable and it has been challenging to improve therapy. The study was published in Oncotarget.
